EXELIXIS, INC. (EXEL) earnings date
Feb 9, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 32 days, typically, give or take 6 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Oct 29, 2026 | after close | 27 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 33 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 32 | 8-K |
| Q4 FY2025 | Tue, Feb 10, 2026 | after close | 39 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 32 | 8-K |
| Q2 FY2025 | Mon, Jul 28, 2025 | after close | 24 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | after close | 39 | 8-K |
| Q4 FY2024 | Tue, Feb 11, 2025 | after close | 39 | 8-K |
What they guided beta
| Q3 FY2026 | "The decrease in collaboration revenues was primarily related to lower milestone-related revenues recognized in the quarter and lower development cost reimbursements earned, partially offset by - more - Exelixis Third Quarter 2026 Financial Results Page 2 of 9 October 29, 2026 higher royalty revenues for the sales of cabozantinib outside the U.S. generated by Exelixis’ collaboration partner Ipsen Pharma SAS (Ipsen)." exhibit |
| Q3 FY2026 | "GAAP net income per share for the quarter ended September 30, 2026 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended September 30, 2026, as compared to the comparable period in 2025, as a result of the stock repurchase programs." exhibit |
| Q3 FY2026 | "Reconciliations between GAAP and non-GAAP results are presented in the tables of this release. - more - Exelixis Third Quarter 2026 Financial Results Page 3 of 9 October 29, 2026 2026 Financial Guidance Exelixis is providing the following updated financial guidance for fiscal year 2026." exhibit |
| Q3 FY2026 | "Current Guidance (provided on October 29, 2026) Previous Guidance (provided on August 5, 2026) Total revenues $2.500 billion - $2.550 billion $2.500 billion - $2.550 billion Net product revenues $2.300 billion - $2.350 billion (1) $2.300 billion - $2.350 billion (1) Cost of goods sold, % of net product revenues ~4% 3.5% - 4.5% Research and development expenses $825 million - $875 million (2) $825 million - $875 million (2) Selling, general and administrative expenses $575 million - $625 million (3) $575 million - $625 million (3) Effective tax rate 16% - 18% 21% - 23% ____________________ (1)" exhibit |
| Q3 FY2026 | "Zanzalintinib GU Highlights Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter of 2027." exhibit |
| Q2 FY2026 | "GAAP net income per share for the quarter ended June 30, 2026 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended June 30, 2026, as compared to the comparable period in 2025, as a result of the stock repurchase programs." exhibit |
| Q2 FY2026 | "Reconciliations between GAAP and non-GAAP results are presented in the tables of this release. - more - Exelixis Second Quarter 2026 Financial Results Page 3 of 9 August 5, 2026 2026 Financial Guidance Exelixis is providing the following updated financial guidance for fiscal year 2026." exhibit |
| Q2 FY2026 | "Current Guidance (provided on August 5, 2026) Previous Guidance (provided on January 11, 2026) Total revenues $2.500 billion - $2.550 billion $2.525 billion - $2.625 billion Net product revenues $2.300 billion - $2.350 billion (1) $2.325 billion - $2.425 billion (1) Cost of goods sold, % of net product revenues 3.5% - 4.5% 3.5% - 4.5% Research and development expenses $825 million - $875 million (2) $875 million - $925 million (2) Selling, general and administrative expenses $575 million - $625 million (3) $575 million - $625 million (3) Effective tax rate 21% - 23% 21% - 23% ________________" exhibit |
| Q2 FY2026 | "Exelixis remains on track to initiate the planned phase 3 STELLAR-316 pivotal trial of zanzalintinib in mid-2026." exhibit |
| Q2 FY2026 | "Zanzalintinib GU Highlights Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/EXEL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/EXEL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/EXEL/"><img src="https://veritasdata.dev/embed/EXEL.svg" alt="EXEL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/EXEL/)
Script
<script async src="https://veritasdata.dev/embed/EXEL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/EXEL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.